Chiropractors in Kingfisher, OK Accepting Medicare
6 Chiropractors found. Showing 1 - 6
 Ashley Cowan Neal, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 212 N Main St, Kingfisher, OK 73750 Phone: 405-375-5483 |
 Palmer Chiropractic Clinic Chiropractor Medicare: Medicare Enrolled Practice Location: 723 S Main St, Kingfisher, OK 73750 Phone: 405-375-5497 Fax: 405-375-5485 |
 Dr. Gary E Palmer, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 723 S. Main Street, Kingfisher, OK 73750 Phone: 405-375-5497 Fax: 405-375-5485 |
Apple Chiropractic Pc Inc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1614 S Main St, Kingfisher, OK 73750 Phone: 405-375-6556 Fax: 405-375-6501 |
Dr. Tamra Dian States, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 1614 S Main St, Kingfisher, OK 73750 Phone: 405-375-6556 Fax: 405-375-6501 |
Dr. Erin Palmer Newell, D.C. Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 723 S Main St, Kingfisher, OK 73750 Phone: 405-375-5497 Fax: 405-375-5485 |
News Archive
New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.
WHO rejects accusations it mishandled H1N1, updates worldwide stats
WHO spokesperson Gregory Hartl on Monday rejected accusations that the organization miscategorized H1N1 (swine flu) as a pandemic, calling such accusations "irresponsible," the Associated Press/Washington Post reports. "WHO also dismissed claims it colluded with drug companies to bring economic benefit to the industry by playing up the danger of the new H1N1 [swine flu] influenza strain," the news service writes.
Waters sales rise 3%, E.P.S. grows 5% in fourth quarter
Waters Corporation reported fourth quarter 2009 sales of $429 million, an increase of 3% from sales of $418 million in the fourth quarter of 2008. In the quarter, foreign currency translation increased sales growth rate by 4% and on a currency neutral basis, sales decreased by 1% in comparison to the prior year's fourth quarter sales. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.08, compared to $1.01 for the fourth quarter of 2008. On a non-GAAP basis, including the adjustments in the attached reconciliation, E.P.S. grew 5% to $1.12 from $1.07 in the fourth quarter of 2008.
Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases
Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.
› Verified 5 days ago
Physical Therapists
Chiropractors
Speech-Language Pathologists
Optometrists
Occupational Therapists